Figure 3.
Figure 3. TZD-induced changes in gA function. Current traces before and after the addition of each of the four TZDs to both sides of a DC18:1PC/n-decane bilayer doped with gA−(13) and AgA(15). In each panel, the top trace was recorded before adding the TZD, and the bottom trace was recorded after the addition. The colored lines denote the current levels for gA−(13) (red line) and AgA(15) (blue line). The four panels show the effects of: (A) 1 µM troglitazone, (B) 30 µM rosiglitazone, (C) 10 µM pioglitazone, and (D) 6 µM ciglitazone. Bars, 3 pA and 30 s.

TZD-induced changes in gA function. Current traces before and after the addition of each of the four TZDs to both sides of a DC18:1PC/n-decane bilayer doped with gA−(13) and AgA(15). In each panel, the top trace was recorded before adding the TZD, and the bottom trace was recorded after the addition. The colored lines denote the current levels for gA−(13) (red line) and AgA(15) (blue line). The four panels show the effects of: (A) 1 µM troglitazone, (B) 30 µM rosiglitazone, (C) 10 µM pioglitazone, and (D) 6 µM ciglitazone. Bars, 3 pA and 30 s.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal